替罗非班在急性心肌梗塞的临床疗效观察

Clinical observation of tirofiban in acute myocardial infarction

目的:对替罗非班在急性心肌梗塞中的临床效果进行了探究。方法:文章在研究中,选择了本院2011年1月至2016年7月的80例急性心肌梗塞患者,均在发病后进行了急诊介入治疗,将80例患者随机分为观察组及对照组,每组患者40例,对照组患者口服阿司匹林、氯吡格雷,并在皮下注射低分子肝素。观察组患者在对照组治疗的基础上,手术时开始使用替罗非班,持续泵入到手术之后的36小时。通过对两组患者治疗变化的分析,确定不良反应的发生。结果:通过对比分析,两组患者在性别、年龄以及合并症等方面均无明显的差异(p<0.05),具有可比性。两组患者在疗效以及安全性比较分析中,评价项目无明显差异(p<0.05),具有可比性。结论:在急性心肌梗塞患者治疗的过程中,使用替罗非班可以减少患者术后心源性死亡、再次心肌梗塞等现象的发生,并改善患者的心脏功能,值得在临床治疗中得到推广。

Objective:To explore the clinical effect of tirofiban in acute myocardial infarction.Methods:In this study,selected 80 cases of acute myocardial infarction patients in our hospital from January 2011 to July 2016,were performed emergency interventional therapy after the onset,80 cases were randomly divided into observation group and control group,40 cases in each group,the control group were treated with aspirin,clopidogrel,and subcutaneous injection of low molecular heparin.Observation group in the control group on the basis of treatment,surgery began using tirofiban,continuous pump into the 36 hours after surgery.Through the analysis of two groups of patients with treatment changes,to determine the occurrence of adverse reactions.Result:In this study,selected 80 cases of acute myocardial infarction patients in our hospital from January 2011 to July 2016,were performed emergency interventional therapy after the onset,80 cases were randomly divided into observation group and control group,40 cases in each group,the control group were treated with aspirin,clopidogrel,and subcutaneous injection of low molecular heparin.Observation group in the control group on the basis of treatment,surgery began using tirofiban,continuous pump into the 36 hours after surgery.Through the analysis of two groups of patients with treatment changes,to determine the occurrence of adverse reactions.Conclusion:In the treatment of patients with acute myocardial infarction,the use of tirofiban can reduce postoperative cardiac death,myocardial infarction and other phenomena occur again,and improve the heart function of patients,is worthy of promotion in clinical treatment.